In vitro susceptibility of Mycoplasma hyosynoviae and M. hyorhinis to antimicrobial agents.
Fifty-four Japanese strains of Mycoplasma hyosynoviae isolated from porkers during 1980 to 1995, and 107 Japanese strains of M. hyorhinis isolated from piglets with respiratory disease during 1991 to 1994 were investigated for the in vitro activities of 13 antimicrobial agents [josamycin, tylosin, spiramycin, kitasamycin, erythromycin, lincomycin (LCM), kanamycin (KM), chloramphenicol (CP), thiamphenicol (TP), tiamulin (TML), oxytetracycline (OTC), chlortetracycline (CTC), and enrofloxacin (ERFX)] by the agar dilution method. Of the drugs tested TML showed the highest activity with minimum inhibitory concentration (MIC) of 0.013 to 0.1 microgram/ m/ (MIC90; 0.05 microgram/ml) against strains of M. hyosynoviae, and 0.2 to 0.78 microgram/ml (MIC90; 0.39 microgram/ml) against strains of M. hyorhinis. ERFX, LCM, most of the 16-membered macrolide antibiotics and tetracyclines also showed low MICs against both mycoplasma species. The susceptibility of KM, CP and TP to the mycoplasmas was considered to be of a secondary grade. Two of 54 strains of M. hyosynoviae, and 11 of 107 strains of M. hyorhinis showed resistance to all 14- and 16-membered macrolide antibiotics tested. Tetracyclines (OTC and CTC) showed a relatively broad MIC distribution from 0.1 to 6.25 micrograms/ml against the M. hyosynoviae strains tested. All of the strains isolated during 1980 to 1984 were susceptible at the concentration of 0.78 microgram/ml or less (MIC90; 0.78 microgram/ml) to OTC and 1.56 micrograms/ml or less (MIC90; 1.56 micrograms/ml) to CTC, while the susceptibility of strains isolated recently, during 1994 to 1995, was more than 0.78 microgram/ml (MIC90; 3.13 micrograms/ml) to OTC, and more than 1.56 micrograms/ml (MIC90; 6.25 micrograms/ml) to CTC.
Kobayashi
H
H
National Institute of Animal Health, Ibaraki, Japan.
Sonmez
N
N
Morozumi
T
T
Mitani
K
K
Ito
N
N
Shiono
H
H
Yamamoto
K
K
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000890:Anti-Infective Agents; D000904:Antibiotics, Antitubercular / Q000494:pharmacology / Q000627:therapeutic use; D002701:Chloramphenicol / Q000494:pharmacology / Q000627:therapeutic use; D004224:Diterpenes / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004352:Drug Resistance, Microbial; D000077422:Enrofloxacin; D004917:Erythromycin / Q000494:pharmacology / Q000627:therapeutic use; D024841:Fluoroquinolones; D066298:In Vitro Techniques; D015570:Josamycin / Q000494:pharmacology / Q000627:therapeutic use; D007612:Kanamycin / Q000494:pharmacology / Q000627:therapeutic use; D015939:Kitasamycin / Q000494:pharmacology / Q000627:therapeutic use; D008034:Lincomycin / Q000494:pharmacology / Q000627:therapeutic use; D009174:Mycoplasma / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D009175:Mycoplasma Infections / Q000188:drug therapy / Q000662:veterinary; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use; D015572:Spiramycin / Q000494:pharmacology / Q000627:therapeutic use; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy; D013752:Tetracycline / Q000494:pharmacology* / Q000627:therapeutic use; D013839:Thiamphenicol / Q000494:pharmacology / Q000627:therapeutic use; D015645:Tylosin / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000904:Antibiotics, Antitubercular; D004224:Diterpenes; D024841:Fluoroquinolones; D015363:Quinolones; D015939:Kitasamycin; D000077422:Enrofloxacin; D007612:Kanamycin; D004917:Erythromycin; D002701:Chloramphenicol; D015572:Spiramycin; D008034:Lincomycin; C014224:tiamulin; D013752:Tetracycline; D013839:Thiamphenicol; D015570:Josamycin; D015645:Tylosin